vs

Side-by-side financial comparison of ALEXANDERS INC (ALX) and BICYCLE THERAPEUTICS PLC (BCYC). Click either name above to swap in a different company.

ALEXANDERS INC is the larger business by last-quarter revenue ($53.3M vs $48.0M, roughly 1.1× BICYCLE THERAPEUTICS PLC). On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs -4.7%). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs -6.9%).

Alexander's, Inc. is a real estate investment trust that owns 7 properties in New York metropolitan area, including 731 Lexington Avenue, the headquarters of Bloomberg L.P. It is controlled by Vornado Realty Trust. It was founded by George Farkas and Louis Schwadron in 1928.

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

ALX vs BCYC — Head-to-Head

Bigger by revenue
ALX
ALX
1.1× larger
ALX
$53.3M
$48.0M
BCYC
Growing faster (revenue YoY)
BCYC
BCYC
+1198.0% gap
BCYC
1193.3%
-4.7%
ALX
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
-6.9%
ALX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ALX
ALX
BCYC
BCYC
Revenue
$53.3M
$48.0M
Net Profit
$-20.2M
Gross Margin
Operating Margin
-51.5%
Net Margin
-42.0%
Revenue YoY
-4.7%
1193.3%
Net Profit YoY
61.1%
EPS (diluted)
$0.75
$-0.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALX
ALX
BCYC
BCYC
Q4 25
$53.3M
$48.0M
Q3 25
$53.4M
$11.7M
Q2 25
$51.6M
$2.9M
Q1 25
$54.9M
$10.0M
Q4 24
$55.9M
$3.7M
Q3 24
$55.7M
$2.7M
Q2 24
$53.4M
$9.4M
Q1 24
$61.4M
$19.5M
Net Profit
ALX
ALX
BCYC
BCYC
Q4 25
$-20.2M
Q3 25
$6.0M
$-59.1M
Q2 25
$6.1M
$-79.0M
Q1 25
$12.3M
$-60.8M
Q4 24
Q3 24
$6.7M
$-50.8M
Q2 24
$8.4M
$-39.8M
Q1 24
$16.1M
$-26.6M
Operating Margin
ALX
ALX
BCYC
BCYC
Q4 25
-51.5%
Q3 25
-558.6%
Q2 25
-2965.8%
Q1 25
-703.7%
Q4 24
Q3 24
-2385.9%
Q2 24
-498.3%
Q1 24
-162.4%
Net Margin
ALX
ALX
BCYC
BCYC
Q4 25
-42.0%
Q3 25
11.2%
-503.7%
Q2 25
11.9%
-2703.8%
Q1 25
22.4%
-608.9%
Q4 24
Q3 24
12.0%
-1898.4%
Q2 24
15.7%
-425.3%
Q1 24
26.2%
-136.0%
EPS (diluted)
ALX
ALX
BCYC
BCYC
Q4 25
$0.75
$-0.29
Q3 25
$1.16
$-0.85
Q2 25
$1.19
$-1.14
Q1 25
$2.40
$-0.88
Q4 24
$2.39
Q3 24
$1.30
$-0.74
Q2 24
$1.63
$-0.77
Q1 24
$3.14
$-0.62

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALX
ALX
BCYC
BCYC
Cash + ST InvestmentsLiquidity on hand
$128.2M
$628.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$109.2M
$610.0M
Total Assets
$1.1B
$717.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALX
ALX
BCYC
BCYC
Q4 25
$128.2M
$628.1M
Q3 25
$286.1M
$648.3M
Q2 25
$313.0M
$721.5M
Q1 25
$319.9M
$793.0M
Q4 24
$338.5M
$879.5M
Q3 24
$354.8M
$890.9M
Q2 24
$410.9M
$961.4M
Q1 24
$526.3M
$457.0M
Total Debt
ALX
ALX
BCYC
BCYC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$30.9M
Q1 24
$30.8M
Stockholders' Equity
ALX
ALX
BCYC
BCYC
Q4 25
$109.2M
$610.0M
Q3 25
$128.3M
$618.5M
Q2 25
$145.4M
$668.9M
Q1 25
$163.1M
$740.3M
Q4 24
$176.9M
$793.1M
Q3 24
$190.7M
$831.0M
Q2 24
$212.5M
$873.8M
Q1 24
$230.1M
$356.0M
Total Assets
ALX
ALX
BCYC
BCYC
Q4 25
$1.1B
$717.6M
Q3 25
$1.3B
$764.0M
Q2 25
$1.3B
$832.2M
Q1 25
$1.3B
$883.9M
Q4 24
$1.3B
$956.9M
Q3 24
$1.4B
$996.7M
Q2 24
$1.5B
$1.1B
Q1 24
$1.4B
$547.1M
Debt / Equity
ALX
ALX
BCYC
BCYC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.04×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALX
ALX
BCYC
BCYC
Operating Cash FlowLast quarter
$73.4M
$-19.3M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-41.5%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-252.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALX
ALX
BCYC
BCYC
Q4 25
$73.4M
$-19.3M
Q3 25
$-9.3M
$-71.2M
Q2 25
$43.6M
$-72.8M
Q1 25
$15.7M
$-86.4M
Q4 24
$54.1M
$-164.7M
Q3 24
$-5.0M
$-39.8M
Q2 24
$11.5M
$-44.6M
Q1 24
$16.8M
$-70.9M
Free Cash Flow
ALX
ALX
BCYC
BCYC
Q4 25
$-19.9M
Q3 25
$-71.8M
Q2 25
$-73.3M
Q1 25
$-87.0M
Q4 24
$-166.0M
Q3 24
$-40.3M
Q2 24
$-45.0M
Q1 24
$-70.9M
FCF Margin
ALX
ALX
BCYC
BCYC
Q4 25
-41.5%
Q3 25
-612.3%
Q2 25
-2509.7%
Q1 25
-871.7%
Q4 24
-4475.7%
Q3 24
-1504.7%
Q2 24
-481.2%
Q1 24
-362.9%
Capex Intensity
ALX
ALX
BCYC
BCYC
Q4 25
1.2%
Q3 25
5.7%
Q2 25
17.1%
Q1 25
6.1%
Q4 24
33.3%
Q3 24
16.3%
Q2 24
4.5%
Q1 24
0.1%
Cash Conversion
ALX
ALX
BCYC
BCYC
Q4 25
Q3 25
-1.55×
Q2 25
7.12×
Q1 25
1.28×
Q4 24
Q3 24
-0.75×
Q2 24
1.37×
Q1 24
1.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons